Additional Investment in Molmir Inc., a Company that 'Sees the Movement of Molecules'
Mitsubishi UFJ Capital has made an additional investment in Molmir Inc., a drug discovery startup with technology to visualize molecular dynamics, to support their ongoing development of novel therapeutics for intractable diseases like ALS.
📋 Article Processing Timeline
- 📰 Published: April 22, 2026 at 20:00
- 🔍 Collected: April 23, 2026 at 00:02 (4h 2m after Published)
- 🤖 AI Analyzed: April 23, 2026 at 05:59 (5h 57m after Collected)
Mitsubishi UFJ Capital Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President: Takuro Kojima) announces that it has made an additional investment in Molmir Inc. (hereinafter "Molmir"), a company that "sees the movement of molecules," from the fund it manages (Mitsubishi UFJ Life Science No. 4 Investment Limited Partnership).
About Molmir
Molmir is building a drug discovery technology development ecosystem based on academia-originated technology seeds with the aim of developing novel therapeutic drugs for intractable diseases, including amyotrophic lateral sclerosis (ALS).
In particular, Molmir possesses a proprietary drug discovery platform technology that visualizes the "movement" of molecules as its core technology. In conventional drug discovery, it was difficult to target "moving" molecules, which account for about 70% of the total. By comprehensively capturing various information of molecules and analyzing molecular dynamics in detail, Molmir realizes a new approach targeting "moving" molecules that could not be targeted before. Furthermore, it increases the probability of drug discovery success by evaluating efficacy on pathology with high accuracy based on molecular dynamics. Through this, it aims to create innovative therapies for a wide range of intractable diseases such as Alzheimer's disease, heart disease, and cancer.
Background of Investment
We were attracted to Molmir's development driving force, which aims to mature its technology by building cooperative relationships with many scientists, in addition to its technology that can comprehensively visualize "moving" molecules in their natural state, and executed our first investment in the seed round in April 2024. Since then, Molmir has pushed forward with securing human resources and developing pharmaceuticals using its core technology, and has succeeded in acquiring a hit compound targeting TDP-43, the causative substance of ALS. We have decided to make an additional investment to highly evaluate this significant progress and to support the expansion of Molmir's future business development. We look forward to Molmir's further leaps forward.
Contact: Mikihiko Shinozaki, Life Science Department
[Overview of Molmir Inc.]
Company name: Molmir Inc.
Location: 840 Shijo-cho, Kashihara-shi, Nara
Representative: Eiichiro Mori
Established: June 2022
Business description: Development of drug discovery platform technologies and pharmaceuticals based on biological phase separation research
URL: https://www.molmir.co.jp/
[About Mitsubishi UFJ Capital Co., Ltd.]
Since its establishment in 1974, Mitsubishi UFJ Capital has provided industry-leading know-how as the venture capital arm of the Mitsubishi UFJ Financial Group, investing in a wide range of industries. We boast an industry-leading track record, with approximately 930 client companies across various industries having achieved an IPO.
In the life science field, since our No. 1 Fund in February 2017, we have continuously established funds totaling 50 billion yen, including the "Mitsubishi UFJ Life Science No. 4 Fund" (20 billion yen). As one of the largest privately-managed funds dedicated to life science in Japan, we invest for a maximum period of about 12 years in venture companies such as drug discovery, regenerative medicine, and medical devices (including digital health). Going beyond bio-venture investments, we also focus on investments in academia drug discovery, pharmaceutical company carve-out projects, pharmaceutical company development projects, and medical device-related areas.
◆Company Overview
Company name: Mitsubishi UFJ Capital Co., Ltd.
Location: Nihonbashi Plaza Building 7F, 2-3-4 Nihonbashi, Chuo-ku, Tokyo
Representative: Takuro Kojima, President
Established: August 1, 1974
Business description: Venture capital business
URL: https://www.mucap.co.jp/
◆About Mitsubishi UFJ Life Science No. 4 Investment Limited Partnership
Investment targets: Life science fields centered on drug discovery, drug discovery platforms, regenerative medicine, medical devices, etc.
General Partner: Mitsubishi UFJ Capital Co., Ltd.
Investors: MUFG Bank, Ltd., Mitsubishi UFJ Capital Co., Ltd.
Established: March 28, 2023
Total fund size: 20 billion yen
About Molmir
Molmir is building a drug discovery technology development ecosystem based on academia-originated technology seeds with the aim of developing novel therapeutic drugs for intractable diseases, including amyotrophic lateral sclerosis (ALS).
In particular, Molmir possesses a proprietary drug discovery platform technology that visualizes the "movement" of molecules as its core technology. In conventional drug discovery, it was difficult to target "moving" molecules, which account for about 70% of the total. By comprehensively capturing various information of molecules and analyzing molecular dynamics in detail, Molmir realizes a new approach targeting "moving" molecules that could not be targeted before. Furthermore, it increases the probability of drug discovery success by evaluating efficacy on pathology with high accuracy based on molecular dynamics. Through this, it aims to create innovative therapies for a wide range of intractable diseases such as Alzheimer's disease, heart disease, and cancer.
Background of Investment
We were attracted to Molmir's development driving force, which aims to mature its technology by building cooperative relationships with many scientists, in addition to its technology that can comprehensively visualize "moving" molecules in their natural state, and executed our first investment in the seed round in April 2024. Since then, Molmir has pushed forward with securing human resources and developing pharmaceuticals using its core technology, and has succeeded in acquiring a hit compound targeting TDP-43, the causative substance of ALS. We have decided to make an additional investment to highly evaluate this significant progress and to support the expansion of Molmir's future business development. We look forward to Molmir's further leaps forward.
Contact: Mikihiko Shinozaki, Life Science Department
[Overview of Molmir Inc.]
Company name: Molmir Inc.
Location: 840 Shijo-cho, Kashihara-shi, Nara
Representative: Eiichiro Mori
Established: June 2022
Business description: Development of drug discovery platform technologies and pharmaceuticals based on biological phase separation research
URL: https://www.molmir.co.jp/
[About Mitsubishi UFJ Capital Co., Ltd.]
Since its establishment in 1974, Mitsubishi UFJ Capital has provided industry-leading know-how as the venture capital arm of the Mitsubishi UFJ Financial Group, investing in a wide range of industries. We boast an industry-leading track record, with approximately 930 client companies across various industries having achieved an IPO.
In the life science field, since our No. 1 Fund in February 2017, we have continuously established funds totaling 50 billion yen, including the "Mitsubishi UFJ Life Science No. 4 Fund" (20 billion yen). As one of the largest privately-managed funds dedicated to life science in Japan, we invest for a maximum period of about 12 years in venture companies such as drug discovery, regenerative medicine, and medical devices (including digital health). Going beyond bio-venture investments, we also focus on investments in academia drug discovery, pharmaceutical company carve-out projects, pharmaceutical company development projects, and medical device-related areas.
◆Company Overview
Company name: Mitsubishi UFJ Capital Co., Ltd.
Location: Nihonbashi Plaza Building 7F, 2-3-4 Nihonbashi, Chuo-ku, Tokyo
Representative: Takuro Kojima, President
Established: August 1, 1974
Business description: Venture capital business
URL: https://www.mucap.co.jp/
◆About Mitsubishi UFJ Life Science No. 4 Investment Limited Partnership
Investment targets: Life science fields centered on drug discovery, drug discovery platforms, regenerative medicine, medical devices, etc.
General Partner: Mitsubishi UFJ Capital Co., Ltd.
Investors: MUFG Bank, Ltd., Mitsubishi UFJ Capital Co., Ltd.
Established: March 28, 2023
Total fund size: 20 billion yen